DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-31

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate safety and initial effectiveness of DS-9231 when taken together with current standard of care. Evaluation will be done with low, medium and then high doses of DS-9231 versus placebo, in participants with medium-risk acute pulmonary embolism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

NCT02923115

Pulmonary Embolism Thrombotic Disease

COMPLETED PHASE1/PHASE2

Diclofenac for Submassive PE

NCT01590342

Pulmonary Embolism

TERMINATED PHASE2/PHASE3

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

NCT02596555

Pulmonary Embolism

TERMINATED PHASE4

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00986154

Venous Thromboembolism Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) +2 more

COMPLETED PHASE3

Clot Dissolving Treatment for Blood Clots in the Lungs

NCT00680628

Pulmonary Embolism

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Ascending doses in sequential cohorts (1-3) will be evaluated against placebo

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DS-9231

In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3

Group Type EXPERIMENTAL

DS-9231

Intervention Type DRUG

DS-9231 in saline solution for intravenous infusion

Placebo

In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo is matching saline solution for intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DS-9231

DS-9231 in saline solution for intravenous infusion

Intervention Type DRUG

Placebo

Placebo is matching saline solution for intravenous infusion

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Investigational product Matching placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Had protocol-defined pulmonary embolism (PE)
* Has stable systolic blood pressure (SBP) \>90 mm Hg
* Has evidence of right ventricular (RV) dysfunction
* Has executed informed consent

Exclusion Criteria

* Has history or plans for thrombotic therapy outside protocol allowance
* Has other contraindications for participation
* Has laboratory results outside protocol-specified limits
* Is pregnant, nursing, and/or not willing or able to use protocol-defined contraceptives
* Has history or condition, or participated in another investigational study that (per protocol or in the opinion of the investigator) might compromise:

1. the safety or well-being of the participant or the participant's offspring
2. the safety of study staff
3. the analysis of results

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No